TEL AVIV (Reuters) - Israel-based healthcare fund aMoon II has secured a $250 million (185 million pounds) investment commitment from Credit Suisse (S:CSGN), the fund’s managing partner Yair Schindel said on Wednesday.
Last month the fund, which is investing in mid- to late-stage companies with a focus on fields like digital health, medical technology and biopharma in Israel, the United States and Europe, said it had raised $200 million from private investors.
The Credit Suisse financing from its asset management and private banking divisions brings the fund close to meeting its target of $500 million. The remainder of the funding is expected to be raised within a few months from other financial institutions and wealthy individuals.
The fund intends to invest $10 million to $40 million in 15 to 20 companies.
aMoon is a life sciences investment fund founded in 2016 by Marius Nacht, co-founder and chairman of Check Point Software Technologies (O:CHKP), and Schindel.
Nacht and Schindel's previous fund, aMoon I, focused on the early stage, investing in 16 startups.